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Abstract
The purpose of the study was to assess whether the occurrence of restenosis is associated with CD45þ platelet count and
neutrophil to lymphocyte ratio in patients with type 2 diabetes mellitus (DM) after drug-eluting stent (DES) implantation for stable
coronary artery disease (CAD). The study comprised 126 patients, including 55 patients with type 2 DM and stable CAD who
underwent elective coronary artery stenting with DES and follow-up angiography within 6 to 12 months. Blood samples were
collected from each patient on the morning of the coronary angiography procedure. The variables related to in-stent restenosis
were selected by logistic regression analysis. The logistic regression analysis showed that 2 inflammatory factors, CD45þ platelet
count (odds ratio [OR] ¼ 4.51, 95% confidence interval [CI]: 1.50-13.50, P ¼ .007) and neutrophil to lymphocyte ratio (OR ¼
3.09, 95% CI: 1.05-9.10, P ¼ .04), were significantly associated with the risk of in-stent restenosis after stenting with DES in
patients with stable CAD and type 2 DM. A receiver operator characteristic curve analysis indicated that the area under the curve
was 0.83% (0.05%; P < .001), which showed that the logistic model had good predictive accuracy (based on CD45þ platelet count
and neutrophil to lymphocyte ratio) for the risk of in-stent restenosis development in DES in patients with CAD and type 2 DM.
Two novel biomarkers of restenosis, CD45þ platelet count and neutrophil to lymphocyte ratio, may be effectively used to predict
in-stent restenosis after DES implantation in patients with CAD and type 2 DM.
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Introduction
Restenosis continues to be a major obstacle to successful cor-
onary artery stenting, and the ability to predict the likelihood of
restenosis occurrence is poor. The attempt to define patients
who benefit most from coronary artery stenting led to a search
for biomarkers for restenosis development. When drug-eluting
stents (DESs) were introduced in clinical practice, the mechan-
ism for the development of in-stent restenosis changed. The
DESs are designed in a way that acute inflammatory reactions
to vessel wall injury and stent struts are attenuated by an anti-
proliferative drug coating. This results in delayed arterial wall
recovery and the persistence of low-grade chronic inflamma-
tion at the place of injury.1 Although the rate of restenosis
decreased significantly after DESs were introduced, a small
percentage of patients still develop in-stent restenosis during
the 6- to 12-month follow-up period. Some studies even sug-
gested a possibility of a late catch-up phenomenon, raising the
question whether DESs may simply delay restenosis develop-
ment.2-4 This prompted the need to discriminate patients with a
higher risk of restenosis in DES, giving rise to a search for
novel biomarkers. To date, many biomarkers of restenosis in
DES are under investigation, but the data are controversial.
Among suggested biomarkers are myeloperoxidase, monocyte
chemotactic protein-1, and cardiotrophin-1.5 Eosinophil catio-
nic protein was identified as a significant predictor of resteno-
sis in the first-generation DESs; they were coated with
sirolimus or paclitaxel, which stimulated hypersensitivity and
an allergic response.6,7 Data on the most studied inflammatory
biomarker, high-sensitive C-reactive protein (hs-CRP), are also
controversial; in some studies, it failed to predict restenosis in
DES,8-10 while it was significant in another study.11 Recently,
several novel biomarkers of restenosis were introduced.
Among them are plasma phospholipids and sphingolipids12
as well as processed B-type natriuretic peptide.13 In our recent
work, we revealed that CD45þ platelet count and neutrophil to
lymphocyte ratio (NLR) predict the development of restenosis
in DES.14 In the present work, we further investigated the pre-
dictive ability of these biomarkers in patients with coronary
artery disease (CAD) and type 2 diabetes mellitus (DM).
This study provides evidence that CD45þ platelet count and
NLR are significant biomarkers for restenosis occurrence after
DES implantation for stable CAD in patients with type 2 DM.
Materials and Methods
Study Patients
The study comprised 126 patients of both genders with stable
CAD, including 55 patients with type 2 DM, consecutively
admitted to the National Medical Research Centre of Cardiol-
ogy, Moscow, Russia, between January 2012 and December
2015 for follow-up angiography, which was 6 to 12 months
after successful elective percutaneous coronary angioplasty
with DES. In all patients, follow-up angiography was condi-
tioned by clinical symptoms. Exclusion criteria were as fol-
lows: age more than 75 or less than 40 years, unstable
angina, myocardial infarction within 2 months prior to stenting,
previous coronary artery bypass grafting or percutaneous cor-
onary intervention, heart failure, abnormal liver or renal func-
tion, active infection, and inflammation. All patients provided
written informed consent, and this study was approved by the
ethics committee of the National Medical Research Centre of
Cardiology.
All patients received DES implantation according to stan-
dard guidelines. Implanted stents were 18 to 33 mm in length
and 2.25 to 3.5 mm in diameter. During the procedure, patients
received a bolus injection of heparin. All patients received
aspirin (100 mg/d) and clopidogrel (300 mg loading dose, fol-
lowed by 75 mg/d for at least 12 months). No patients had
major procedure-related complications. During the observation
period, all patients received statins and, if required, antianginal
and antihypertensive therapies. Patients’ demographic and
clinical characteristics, as well as their coronary angiographic
information, were collected carefully at baseline prior to per-
cutaneous coronary intervention and follow-up angiography.
In-stent restenosis was defined as a stenosis diameter of
50% occurring in the segment inside the stent or 5 mm prox-
imal or distal to the stent at follow-up angiography. Type 2 DM
was defined as either a previous diagnosis of DM treated with
diet, oral agents, or insulin or a new diagnosis of DM if fasting
blood glucose is 7.0 mmol/L on 2 occasions.
Laboratory Analysis
Blood samples were collected from each patient on the morn-
ing of the coronary angiography procedure. Blood was taken
from the patients versus cubitalis in vials containing EDTA.
Blood measurements, including neutrophils, monocytes, lym-
phocytes, basophils, eosinophils, and platelets, were performed
on whole blood. Blood for laboratory analysis was centrifuged
for 20 minutes at 2000g. The supernatant was stored at 38C.
Plasma levels of total cholesterol, low-density lipoprotein cho-
lesterol, high-density lipoprotein cholesterol, triglyceride, glu-
cose, creatinine, and hs-CRP were measured in all patients.
Identification of CD45þ Platelet
Patients’ blood was collected by cubital venipuncture and
anticoagulated with 3.8% sodium citrate at an anticoagulant
to blood ratio of 1:9. Platelet-rich plasma (PRP) was separated
by centrifugation at 150g for 10 minutes at room temperature.
The supernatant was aspirated and stored at room temperature
no longer than 4 hours. Platelet-poor plasma was prepared by
centrifugation of the blood at 2000 g for 15 minutes. We iden-
tified platelet-specific CD41 antigen glycoprotein IIb (GP IIb)
in the GP IIb–IIIa complex and a leukocyte-specific CD45
antigen expressed by all leukocyte types using monoclonal
antibodies conjugated with phycoerythrin (PE) and CY5-PE,
respectively. Mouse-conjugated immunoglobulins of similar
isotypes were used as a control. All antibodies were from
“Becton Dickinson.” For the analysis of antigen expression,
100 mL of 2 mM EDTA in 0.1 M phosphate-buffered saline
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(rN 7.4) was added to 100 mL PRP, and the mixture was fixed
with 200 mL of 2% paraformaldehyde in a phosphate buffer and
stored at 4oS for no longer than 4 days. Antibodies (10 mL)
were incubated with fixed PRP (5 mL) at room temperature for
40 minutes in the dark; then, a 500-mL phosphate buffer was
added, and the samples were analyzed in an FACS Calibur flow
cytofluorometer (Becton Dickinson).
Statistical Analysis
Values displaying normal distribution were expressed as the
mean (standard deviation), and values with skewed distribution
were expressed as the median (lower quartile; upper quartile).
To check hypotheses related to the type of distribution, the
Shapiro-Wilk W test was used. Patients were compared using
a nonparametric 2-tailed Fisher exact test or Mann-Whitney U
test for comparing 2 unmatched samples and a Kruskal-Wallis
analysis of variance by ranks test for comparing 3 or more
samples.
To construct the logistic model and subsequently deter-
mine the independent risk factors for stent restenosis, the
essential variables derived from binary comparisons were
assessed via logistic regression analysis. A receiver-operator
characteristic (ROC) curve was constructed to determine the
logistic model’s predictive value. Differences were consid-
ered to be statistically significant if the null hypothesis could
be rejected with >95% confidence interval (CI). The statistical
analysis was carried out using SPSS Statistics software
version 17.0 (SPSS Inc.: Chicago, USA).
Results
The study comprised 126 patients with stable CAD in whom
217 DES have been implanted. Patients were divided into 2
groups according to the presence of type 2 DM. The first group
comprised 55 patients with type 2 DM, and the second group
consisted of 71 patients without type 2 DM. Clinical charac-
teristics of patients of both groups at the time of stenting are
presented in Table 1. The distribution of patients between the
groups did not differ significantly in age, gender, or tobacco
smoking status, as well as incidence of hyperlipidemia, arterial
hypertension, or previous myocardial infarction. Restenosis
occurred more frequently in patients with DM: 30 (54.5%) of
restenosis cases in patients with type 2 DM versus 23 (32.4%)
of restenosis cases in patients without type 2 DM (P ¼ .01).
Angiographic characteristics of patients at the time of
stenting are presented in Table 2. The average number of
implanted stents, stenting of left anterior descending, circum-
flex, and right coronary arteries, as well as stenting of occlu-
sions and diffuse lesions, did not differ between the groups.
Patients with type 2 DM underwent stenting of arteries with
small (2.75 mm) diameter DESs more frequently than
patients without type 2 DM in 27 (49.1%) and 23 (32.4%)
cases, respectively (P ¼ .09).
Risk Factors for Restenosis Development
We applied a binary logistic regression analysis to obtain
the binary comparisons of more than 35 different clinical,
laboratory, and angiographic variables and define significant
risk factors for restenosis development. Five factors were
identified as the most significant (see Table 3). In patients
with type 2 DM, CD45þ platelet count (odds ratio [OR] ¼
4.51, 95% CI: 1.50-13.50, P ¼ .007) and NLR (OR ¼ 3.09,
95% CI: 1.05-9.10, P ¼ .04) were significant. Angiographic
factors were not significant in this group (Figure 1A). These
factors were stenting of arteries with small diameter (<2.75
mm; OR ¼ 1.08, 95% CI: 0.38-3.13, P ¼ .88) and the
number of simultaneously implanted stents (OR ¼ 1.19,
95% CI: 0.80-1.79, P ¼ .39).
Table 1. Baseline Clinical Characteristics.a
Parameter
Patients With
Diabetes Mellitus,
n ¼ 55
Patients Without
Diabetes Mellitus,
n ¼ 71 P
Age, years 62.4 (9.5) 62.2 (11.3) .92
Males/females 41 (75)/14 (25) 54 (76)/17 (24) .90
Myocardial infarction in
anamnesis
29 (52.7) 49 (69) .07
Arterial hypertension 54 (98.2) 65 (91.2) .11
Hyperlipidemia 55 (100) 70 (98.6) .81
Smoking 28 (50.9) 34 (47.9) .74
In-stent restenosis 30 (54.5) 23 (32.4) .01
One major coronary
artery
32 (58.2) 48 (67.6) .36
Two major coronary
arteries
14 (25.5) 18 (25.4) .99
Three major coronary
arteries
32 (16.4) 5 (70) .10
Abbreviation: SD, standard deviation.
aValues are given as the absolute number of patients (% total number). Age is
given as mean (SD).
Table 2. Baseline Angiographic Characteristics.a
Parameter
Patients With
Diabetes Mellitus,
n ¼ 55
Patients Without
Diabetes Mellitus,
n ¼ 71 P
Number of stents per
patient
2.2 (1.4) 1.9 (1.1) .18
Left anterior descending
artery
33 (60) 43 (60.6) .91
Circumflex artery 20 (36.4) 29 (40.8) .65
Right coronary artery 32 (58.2) 31 (43.7) .12
Bifurcation stenosis 0 (0) 2 (2.8) .21
Occlusion 16 (29.1) 23 (32.4) .72
Diffuse stenosis >20 mm 31 (56.4) 42 (59.2) .74
Artery diameter 2.75
mm
27 (49.1) 23 (32.4) .09
Abbreviation: SD, standard deviation.
aData are absolute values of implanted stents (with the percentage in parenth-
eses). The number of implanted stents is given as mean (SD).
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The results were virtually the opposite in patients without
type 2 DM. In this group, stenting of arteries with small
diameter (OR ¼ 6.7, 95% CI: 2.2-30.4, P ¼ 0.001) and the
number of implanted stents (OR ¼ 2.99, 95% CI: 1.43-6.27,
P ¼ .002) were significant factors associated with restenosis.
In the group without type 2 DM, inflammatory biomarkers’
significance was diminished (Figure 1B). CD45þ platelet
count had OR ¼ 2.31 (95% CI: 1.70-5.00, P ¼ .007), and
NLR was not significant (OR ¼ 1.55, 95% CI: 0.86-2.81,
P ¼ .15). We found that the hs-CRP level was not a reliable
predictor of restenosis in both groups: OR ¼ 0.95 (95% CI:
0.69-1.25, P ¼ .71) for the group with type 2 DM and
OR ¼ 0.65 (95% CI: 0.36-1.18, P ¼ .45) for the group
without type 2 DM.
We performed a multiple logistic regression analysis to con-
struct the logistic model and identify independent predictors of
restenosis development in patients with type 2 DM. The choice
of the strongest combination of independent variables was
based on the highest predictive potential and the highest per-
centage of findings, which were precisely predicted by the
model. The logistic model includes 3 independent predictors:
CD45þ platelet count, NLR, and type 2 DM. Other variables
were excluded from the model because they were insignificant.
The logistic regression equation for prognosis of restenosis in
DESs in patients with CAD and type 2 DM was formulated as
follows:
Y ¼ b0þ b1 X1þ b2 X2þ b3 X3;
where X1 is content of CD45þ platelet, X2 is NLR, and X3 is
type 2 DM. Coefficient values b0 to b3 of the logistic model
and their ODs, 95% CI, and statistical significance of each
coefficient are given in Table 4. The probability of restenosis
development was calculated as follows:
P ¼ expðY Þ
1þ expðY Þ :
The model possesses a high-efficiency index of predictive
ability with 83% diagnostic precision. The model demonstrates
a high-level OD, which equals 15.1 (P < .01). To determine the
predictive power of the logistic model with the results of the
logistic regression analysis of findings (n ¼ 126), we built a
ROC curve. The area under the curve was 0.83% (0.05%; P <
.001). Thus, the power of the logistic model for predicting
restenosis development in patients with CAD and type 2 DM
should be considered very high.
Table 3. Risk Factors for Restenosis Occurrence in Patients With Type 2 DM and CAD, Identified With Binary Logistic Regression Analysis.a
Parameter All Patients, n ¼ 126 Patients With DM, n ¼ 55 Patients Without DM, n ¼ 71
DM 2.50 (1.21-5.18)b - -
CD45þ platelet 2.91 (1.70-5.00)b 4.51 (1.50-13.50)b 2.31 (1.70-5.00)b
Neutrophil to lymphocyte ratio 1.61 (1.15-2.25)b 3.09 (1.05-9.10)b 1.55 (0.86-2.81)NS
Number of stents 1.68 (1.19-2.28)b 1.19 (0.80-1.79)NS 2.99 (1.43-6.27)b
Arterial diameter 2.75 mm 2.99 (1.43-6.28)b 1.08 (0.38-3.13)NS 6.7 (2.2-30.4)b
Abbreviations: CAD, coronary artery disease; CI, confidence interval; DM, diabetes mellitus; NS, not significant; OR, odds ratio.
aData are absolute values of OR with 95% CI.
bP < .05.
Figure 1. Risk variables for restenosis identified using binary logistic regression analysis. A, Patients with coronary artery disease and type 2
diabetes mellitus; B, patients with coronary artery disease but without type 2 diabetes mellitus. Data are absolute values of OR with 95% CI. CI
indicates confidence interval; hs-CRP, high-sensitive C-reactive protein; NLR, neutrophil to lymphocyte ratio; OR, odds ratio.
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Sample Size Calculation
We investigated 126 patients in which 53 cases of restenosis
occurred and 3 variables were cogent predictors of restenosis in
the logistic model. The number of events per predictive vari-
able was 53/3 ¼ 17.6 for the full sample. The logistic regres-
sion analysis demands at least 10 events for 1 variable to verify
the statistical significance of a variable.15 Thus, the sample size
was sufficient to verify the significance of acquired variables.
Discussion
We found that CD45þ platelet counts are increased in the
blood of patients with CAD and type 2 DM. The CD45 antigen
has a leukocyte origin. Its appearance on platelets is strong
evidence of interactions between leukocytes and platelets.
However, the mechanisms through which these cells interact
remain unknown. They could involve direct cell-to-cell contact
or microparticle-mediated contact. In the latter case, micropar-
ticles transfer the membrane proteins of parent cells to the
target cells. It has been proven that leukocytes generate micro-
particles.16 More specifically, they shed microparticles under
conditions of acute injury and inflammation. There are experi-
mental data demonstrating that the interaction and binding of
microparticles to target cells may be facilitated by adhesion
receptors,17-19 and such interactions may affect the functional
activity of cells. Microparticle-facilitated platelet–leukocyte
interactions are well established.19
Platelets with a CD45 leukocyte antigen appear in circula-
tion probably due to the capture of leukocyte microparticles.
They were recently detected in the blood of patients with myo-
cardial infarction.20 In our recent work, we showed that
increased counts of platelets with CD45 leukocyte antigens are
characteristic for patients with restenosis in DES.14 In the pres-
ent article, we demonstrate that patients with type 2 DM and in-
stent restenosis in DES have higher counts of CD45þ platelet
in circulation than patients with in-stent restenosis in DES but
without type 2 DM (OR: 4.51 vs 2.31, respectively). Consid-
ering the opinion that chronic inflammation underlies resteno-
sis development after DES, the increased CD45þ platelet count
may reflect a higher level of platelet–leukocyte interactions. It
is not clear whether this interaction is a result of local inflam-
matory activation of cells near the stent placement, or it
just reflects the propensity for a more active inflammatory
response. The possible corroboration of the latter statement
comes from the fact that full recovery of the endothelium and
neointima takes no more than several months, and our findings
were made 6 to 12 months after the stents were implanted. This
may imply that increased CD45þ platelet counts are due to
increased inflammatory activity rather local cell activation near
the stent.
Another finding is that elevated NLR may serve as an inde-
pendent predictor of in-stent restenosis in DES in patients with
type 2 DM. Elevated NLR is a characteristic of inflammation. It
has emerged in recent years as an independent predictor of
major adverse cardiovascular events and mortality,21,22 as well
as a predictor of in-stent restenosis in bare-metal stents.23-25 In
our recent work, we have already reported elevated NLR in
persons with restenosis in DES.14 This was found in the general
population. In the present work, we demonstrate that in patients
with type 2 DM and in-stent restenosis in DES, NLR is elevated
even more than in the general population with restenosis (OR:
3.09 vs 2.68, respectively).
In this study, hs-CRP was not a significant predictor of rest-
enosis in DES in patients with type 2 DM. This finding is in line
with the results of previous studies, where hs-CRP failed to
predict restenosis in DES.8-10 There was no apparent methodo-
logical error. We suggest that there might be some other reason.
Intriguingly, there are data showing that CRP has 2 isoforms.26
It is synthesized in the liver under inflammatory conditions as a
pentameric form, which is putatively inactive. The following
conformational rearrangement in the area of local inflamma-
tion leads to the dissociation of pentameric CRP (pCRP) into 5
monomeric parts, which are not detectable by hs-CRP assay.
These parts, named monomeric CRP (mCRP), are reportedly
accountable for CRP’s pro-inflammatory activity.26 There are
data demonstrating that mCRP but not pCRP can activate the
endothelium27,28 in vitro. It has also been found in vivo on
circulating microparticles in persons with acute myocardial
infarction.29 Also, mCRP deposits were described in autopsy
samples of carotid atheroslerotic plaques, without pCRP traces
in the same plaques.30 These novel data may provide the
answer to discrepancies in results in hs-CRP measurements
in patients with cardiovascular disease.
We shall also consider the fact that angiographic character-
istics were not significant as predictors of restenosis in DES in
patients with type 2 DM. It could be said that in patients with
DES implantation and a strong pro-inflammatory condition
Table 4. Independent Predictors of Stent Restenosis in the Logistic Equation.a
Variable B SE Wald Degrees of Freedom P Value OR
95% CI for OR
Lower Upper
X1 2.388 0.747 10.222 1 .001 10.895 2.520 47.104
X2 0.622 0.261 5.684 1 .017 1.863 1.117 3.107
X3 1.260 0.578 4.760 1 .029 3.526 1.137 10.938
Constant 3.528 1.036 11.598 1 .001 0.029 - -
Abbreviations: CI, confidential interval; OR, odds ratio; SE, standard error.
aVariables: X1 represents CD45þ platelet, X2 represents neutrophil to lymphocyte ratio, and X3 represents type 2 diabetes mellitus.
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such as DM, the inflammatory biomarkers should be preferred
over noninflammatory. It is worth mentioning that in patients
without type 2 DM, noninflammatory characteristics were the
best predictors of restenosis in DES. In this group, stenting of
small diameter arteries and the number of implanted stents
provides impressive 6.7 and 2.99 OR, while inflammatory
characteristics lose significance (Figure 1).
The results of this study make it possible to suggest that the
further search for biomarkers of restenosis in DES could ben-
efit from directing efforts into studying different biomarkers
for specific conditions. Thus, we may strengthen the inherent
predictive power of biomarkers by choosing inflammatory
biomarkers to predict in-stent restenosis in patients with pro-
inflammatory conditions such as type 2 DM or noninflamma-
tory biomarkers to predict restenosis in patients without the
propensity to develop chronic inflammation.
Conclusions
Two novel biomarkers of restenosis, CD45þ platelet count and
NLR, may be effectively used to predict in-stent restenosis
after DES implantation in patients with CAD and type 2 DM.
Study Limitations
This is a retrospective study. Coronary angiography was not
routinely performed in every patient after stent implantation.
Follow-up coronary angiography was performed predomi-
nantly in patients presenting with recurrent angina pectoris.
Many factors are associated with restenosis development after
coronary stenting, so it cannot be excluded that additional fac-
tors which have not been assessed in our study could have a
similar influence on restenosis development. We do not know
the baseline CD45þ platelet levels in patients who participated
in this investigation, whether the patients with restenosis had
changes in the levels of CD45þ platelet at baseline or whether
this difference is a consequence of stent implantation.
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